Click here to load reader

Avoca CenterWatch Insider Insights Article

  • View

  • Download

Embed Size (px)

Text of Avoca CenterWatch Insider Insights Article

  • 1.Breaking News andMarket Intelligence for March 26, 2012 the Clinical Trials IndustryAbbott names new research-basedA CenterWatch Publicationcompany AbbVie2Canadian government renews partnership withRx&D to boost nations clinical trial industry3inVentiv to acquire Kforce Clinical Research,The Pulse on Latin America6adding more FSP depth to its staffing servicesiDrug & Device Pipeline News7nVentiv Health is about to surge more But the addition of Kforce Clinical gives the CenterWatch has identified 18 drugsdeeply into the functional service pro- company even more depth and flexibility and devices that have entered a newvider (FSP) that realm, said Gregg Dearhammer, trial phase this week.Last week the CRO announced it waspresident of FSP/Staffing for inVentiv, andbuying Kforce Clinical Research, the clini- formerly president and CEO of i3 StatprobeTrial Results8CenterWatch reports on results forcally focused arm of publicly traded, Tampa,before inVentiv bought i3.four drugs. Visit www.centerwatch.comFla.-based staffing firm Kforce, which in the We believe that now, with the Kforce ad- for real-time updates on drugs inlast few years has grown its clinical staffingdition, we have an interesting offering thatclinical trials.division into a robust FSP offering.not many can match, said Dearhammer.inVentiv is paying $50 million for Kforce We can now offer short-term staffing and Biotech Review9Clinical. The deal is expected to close by thecomplex FSP help all under the same roof so Biotech briefs from BioWorld Today.end of the month. that when sponsors staffing needs shift andCWMarketPlace10inVentivwhich started out primarily as change, they dont have to go elsewhere for Industry service provider profiles.a staffing, sales and communications firm help. We can offer flexibility if they changeserving pharma companies, but then grew their minds. CenterWatch Information Servicesexponentially last year with its purchase ofNeal McCarthy, managing director ofThe CenterWatch Monthlyi3 and Pharmanetalready has a leader-investment firm Fairmount Partners and aA monthly newsletter featuring in-depth storiesship position in the staffing and FSP space. page 4 on the clinical trials industry and grant opportunities.Annual subscriptions start at $399.JobWatchSurvey: Sponsor-CRO strategic partnerships web-based service listing clinical research jobs,always work, poor quality and performance cited career resources and a searchable resume database.SClinical Trials Listing Service trategic partnership agreementsThe results of Avocas annual State of international listing service of actively enrolling between sponsors and CROs have ical Outsourcing Industry Survey, just releasedclinical trials to support sponsors and CROs in their been all the rage over the last year orthis month, showed a whopping 22% ofpatient enrollment But are they working out well?the 244 respondents (147 sponsors and 97Market Research ServicesWhile the curtain has been largely drawnclinical service providers) had discontinuedCustom surveys for organizations to gain competitiveon that, except for the occasional commenta strategic partnership agreementand not insight into the market and their business. Contact SteveZisson, (617) 948-5142, [email protected] a CRO or sponsor, the industry now has because a sponsor decided to go from, say,Drugs in Clinical Trials Databaseits first real look. Research and consultingfour partners down to two. Rather, qualityA searchable database of 4,000+ detailed profiles of newfirm The Avoca Group surveyed sponsorswas the issue. Poor quality and performance drugs in development in hundreds of disease conditionsand CROs about their interactions in the out- was cited by 85% of those who said they worldwide. Request a 5-day trial. Contact Sales,(617) 948-5100, [email protected] space, and in doing so asked somehad severed a strategic partnership agree-CenterWatch Publicationsvery provocative questions about strategicment. CenterWatch publishes a wide range of CME-accreditedpartnership agreements. To Patricia Leuchten, CEO of The Avocatraining guides, directories, brochures and drug intelligenceinformation. Visit the most revealing: Have youGroup, this came as a shock. Companiesever discontinued one? page 5 CenterWatch Main and Editorial Offices10 Winthrop Square, Fifth Floor, Boston, MA 02110Tel (617) 948-5100 Fax (617) 948-5101Volume 16, Issue 12. Copyright 2012 by CenterWatch. All rights [email protected]

2. CWWeekly March 26, 2012 2 of 10Industry BriefsSponsorsincluding custom quantitative research and The Trudeau Institute, a Saranac Lake,analytics; qualitative research; key opinion N.Y.-based research center, has expanded the Abbott has dubbed its new, independent leader identification and mapping; message scope of its biomedical research by creat- research-based pharmaceutical companytracking, including Rapid Recall (SM) mes- ing a nonprofit CRO, the Trudeau Institute AbbVie (pronounced Abb-vee), which itsage effectiveness studies; syndicated auditsContract Research Organization (TICRO). will launch by the end of 2012. Abbott chose including the Metropolitan Area Promotion- The expansion is in response to the drug the name as a combination of Abbott andal Audit, which tracks promotional activityindustrys increased reliance on CROs for vie, which is a reference to the Latin root vi across 15 specialty therapeutic areas; and specialty research to reduce the costs and meaning life.The beginning of the namea range of SDI Health medical and promo- delays associated with the development of connects the new company to Abbott and tional audits acquired from IMS vaccines and therapeutics. As experts in its heritage of pioneering science. The vie the immunological, biological and molecular calls attention to the vital work the company CRO QED Clinical Services has createdbasis of infectious diseases and immune dis- will continue to advance to improve the livesa wholly owned subsidiary, QED Clinicalorders, Trudeau scientists will offer their ex- of people around the world, said Richard A. Services India Private Limited, in Ahmedabad,pertise and models through TICRO. The new Gonzalez, executive vice president of global India, to enhance its global delivery of clinicalCRO will provide project-specific expertise to pharmaceuticals at Abbott. Gonzalez will trials. The subsidiary adds operational andbiopharmaceutical companies and academic head AbbVie as chairman and CEO. Last Oc-therapeutic expertise to QED, and expands itsresearchers, assist clients with the design tober Abbott announced it would separate capacity and capability to offer more global and execution of efficient studies with into two publicly traded companies, one in coverage. QED operations in India will bewell-defined endpoints and help accelerate diversified medical products and the other spearheaded by country head and director the drug development process. The Institute in research-based pharmaceuticals. AbbVie, of operations Ali Saijad Bohra, who has ledhopes to develop translational research part- the research-based company, will include clinical monitoring, FSP models and projectnerships with biotech and pharmaceutical Abbotts current portfolio of pharmaceuti- management across India, Southeast Asia, companies and help bring new therapeutics cals and biologics. The diversified medicalJapan, South Korea and Australia. India and to patients safely and more efficiently. products company, which will retain thethe Asia Pacific region will continue to have Abbott name, will consist of Abbotts existing focus and will remain key markets for the R&D trends diversified medical products portfolio.drug development activities for biopharma-ceutical companies on account of a variety of The quality of dementia research in the U.K.CROs/Service providersbenefits, said Bohra. In addition to conduct- is second only to the U.S., despite the lowing trials in India, QED India will act as a hub number of scientists working in the field, and Campbell Alliance, an inVentiv Healthfor QEDs Asia Pacific operations for controlfinding a cure can be accelerated by increas- company and management consulting firm,and oversight of its local partners across the ing the number of dementia researchers and has launched Encuity Research, a marketregion. The creation of QED Clinical, India investment, according to the Intellectual research and analytics subsidiary. The means that we can better meet the global Property & Science business of Thomson launch immediately follows the acquisition development needs of our sponsors by Reuters. The findings are featured in an of SDI Healths promotional and medicalgiving access to vast patient populations viaAlzheimers U.K. research report titled Defeat- audit businesses from IMS Health, whichregional experts on the ground, said CEOing Dementia. The analysis revealed the U.K. closed March 20. The audit businesses Thomas 3 acquired from IMS will be combined with our existing market research and analytics CWWeekly (ISSN 1528-5731) 2012 CenterWatch, LLC. All rights reserved. service lines to create a business that will Cheryl Appel Rosenfeld Editor-in-ChiefNo part of this publication may be distributed orTracy Lawton Drug Intelligencereproduced in any form or by any means without the drive accelerated growth for us in the mar-Melissa Nazzaro Advertising express written consent of the publisher. Permission ket research segment, said Nader Naeymi-Heather Johnston Advertisingrequests can be obtained via fax at (617) 948-5101 orHolly Rose Production emailed at [email protected] Rad, CEO of Campbell Alliance. Encuity Single-user annual subscriptions are $249. Research, to be based in Newton, Penn.,Send news submissi

Search related